Nan Fung Group Holdings’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Nan Fung Group Holdings’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,300	Closed	-$336K	–	42
2023 Q2	$336K	Buy	+3,300	New	+$312K	0.22%	32
2022 Q4	–	Sell	-8,265	Closed	-$208K	–	45
2022 Q3	$208K	Hold	8,265	–	–	0.13%	32
2022 Q2	$251K	Hold	8,265	–	–	0.17%	33
2022 Q1	$271K	Hold	8,265	–	–	0.13%	37
2021 Q4	$218K	Hold	8,265	–	–	0.06%	45
2021 Q3	$832K	Hold	8,265	–	–	0.27%	23
2021 Q2	$1.17M	Buy	+8,265	New	+$933K	0.36%	21

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Nan Fung Group Holdings's RETA Position: Q3 2023 in Review

Nan Fung Group Holdings sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 3,300 shares — an estimated $336K sold.

Nan Fung Group Holdings first reported a position in RETA in Q2 2021 and held it in 7 quarters. The position peaked at $1.17M in Q2 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Nan Fung Group Holdings reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Nan Fung Group Holdings sold 3,300 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $336K.
Nan Fung Group Holdings first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2021 and held it in 7 quarters.
Nan Fung Group Holdings's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.17M in Q2 2021.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Nan Fung Group Holdings's 13F filing for Q3 2023, filed 13 Nov 2023.